流行病學(xué)第七章篩檢_第1頁(yè)
流行病學(xué)第七章篩檢_第2頁(yè)
流行病學(xué)第七章篩檢_第3頁(yè)
流行病學(xué)第七章篩檢_第4頁(yè)
流行病學(xué)第七章篩檢_第5頁(yè)
已閱讀5頁(yè),還剩76頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、 第七章 篩檢ScreeningStage of susceptibilityStage of Subclinical DiseaseStage of Clinical Disease Stage of Recovery,Disability, or DeathExposurePathological ChangesOnset ofSymptomsUsual Time of Diagnosis疾病自然史(Natural History of Disease)疾病自然史與篩檢Natural History of Disease and Screening開(kāi)始暴露出現(xiàn)癥狀臨床前可檢查期 疾病發(fā)生診

2、斷治療 如果疾病在臨床前期出現(xiàn)一些可以識(shí)別的異常特征,如腫瘤的早期標(biāo)識(shí)物(biomarkers)、血壓升高、血脂升高等,則可使用一種或多種方法將其查出,并對(duì)其做進(jìn)一步的診斷和治療,則可延緩疾病的發(fā)展,改善其預(yù)后 引 言易感期 臨床前期 臨床期 殘疾、死亡 康 復(fù)Pathological Changes開(kāi)始暴露出現(xiàn)癥狀臨床前可檢查期 疾病發(fā)生診斷治療篩檢Screening 引 言康 復(fù)殘疾、死亡 易感期 臨床前期 臨床期 疾病自然史與篩檢Natural History of Disease and Screening目 錄 概述 篩檢試驗(yàn)的評(píng)價(jià) 篩檢效果的評(píng)價(jià)Introduction Evalu

3、ation of screening testEvaluation of effectivenessOutline篩檢是運(yùn)用快速、簡(jiǎn)便的試驗(yàn)、檢查或其他方法,將健康人群中那些可能有病或缺陷,但表面健康的人、同那些可能無(wú)病者鑒別開(kāi)來(lái) Screening is defined as the use of quick and simple testing procedures to identify and separate persons who are apparently well, but who may be at risk of a disease, from those who pro

4、bably do not have the disease.第一節(jié) 概述Introduction根據(jù)所用的篩檢方法的數(shù)量多少單項(xiàng)篩檢多項(xiàng)篩選篩檢的分類Categories of screeningBased on the on the quantity of screening methodsSingle screening Multiple screening根據(jù)篩檢對(duì)象的范圍不同整群篩檢 選擇性篩檢篩檢的分類Categories of screeningBased on the scope of screening subjects Mass screening Selective scr

5、eening篩檢試驗(yàn)Screening test 是用于識(shí)別外表健康的人群中可能患有某疾病的個(gè)體或未來(lái)發(fā)病危險(xiǎn)性高的個(gè)體的方法。Screening is the detection of patients, suspected patient and high risk of the disease in healthy population .篩檢試驗(yàn)Screening test 問(wèn)卷、常規(guī)體格檢查、物理學(xué)檢查、實(shí)驗(yàn)室檢驗(yàn)、分子生物學(xué)技術(shù)Questionnaire, routine physical examination, physical examination, laboratory

6、tests, molecular biology techniques 簡(jiǎn)單性 廉價(jià)性 快速性 安全性 可接受性篩檢試驗(yàn)應(yīng)具備五個(gè)特征Five characteristics that screening test should have Simple Cheap Quick Safe Acceptable二級(jí)預(yù)防一級(jí)預(yù)防疾病的自然史 篩檢的目的Secondary prevention Primary prevention Natural history of disease Purposes of screening診斷試驗(yàn)是指應(yīng)用實(shí)驗(yàn)、儀器設(shè)備等手段對(duì)疾病進(jìn)行診斷的一切檢測(cè)方法。 Diag

7、nostic test is to distinguish diseased from the non-diseased but suspected to have disease. 診斷試驗(yàn)Diagnostic test包括各種實(shí)驗(yàn)室檢查、影像診斷、儀器檢查,還包括病史詢問(wèn)、體格檢查等。Laboratory tests, imaging diagnosis, Instrumental test, history report and physical examinationApparently Well Population to be TestedScreening TestDiagnos

8、tic TestDisease or Risk Factor PresentDisease or Risk Factor AbsentNegatives (Normal) (Persons presumed to be free of disease)Negative on screeningPositive on screen, no disease Positive on screen, disease presentPositives (abnormal)presumed tohave diseaseTreatment Intervention篩檢試驗(yàn)流程圖 Flow diagram o

9、f screening test篩檢試驗(yàn)與診斷試驗(yàn)的區(qū)別Distinguish between screening test and diagnostic test篩檢試驗(yàn)Screening test診斷試驗(yàn)Diagnostic test對(duì)象健康人或無(wú)癥狀的病人病人目的發(fā)現(xiàn)可疑病人對(duì)病人進(jìn)行確診要求快速、簡(jiǎn)便、安全,高靈敏度 復(fù)雜、準(zhǔn)確性和特異度高 費(fèi)用經(jīng)濟(jì)、廉價(jià)花費(fèi)較高 處理用診斷試驗(yàn)確診 嚴(yán)密觀察和及時(shí)治療 第一節(jié) 概 述篩檢的疾病是當(dāng)?shù)匾粋€(gè)重大的公共衛(wèi)生問(wèn)題具備有效的治療或預(yù)防方法應(yīng)用篩檢的原則 Principles for the application of screeningThe

10、 disease being screened should be a major problemAcceptable treatment or prevention methods should be available for individuals with diseases discovered in the screening process有進(jìn)一步確診的方法與條件該病的自然史明確A suitable and effective test or examination for the disease should be available The natural history of

11、 the disease should be adequately understood應(yīng)用篩檢的原則 Principles for the application of screening該病具有較長(zhǎng)的潛伏期或領(lǐng)先時(shí)間預(yù)期有良好的篩檢效益The disease should have a recognizable course, with early and latent states of the disease being identifiableExpected good efficiency of screening should be available應(yīng)用篩檢的原則 Princi

12、ples for the application of screening 篩檢方法 Good screening test 確診方法 Appropriate diagnostic method 有效的治療手段 Effective treatment 三者缺一不可,否則將導(dǎo)致衛(wèi)生資源浪費(fèi),給篩檢試驗(yàn)陽(yáng)性者帶來(lái)生理和心理上的傷害等不良后果第一節(jié) 概 述 基本條件Basic criteria for a successful screening program倫理學(xué)問(wèn)題Ethical Issues 尊重個(gè)人意愿 Respect for persons will 有益無(wú)害 Useful and ha

13、rmless 公正 Fairness第二節(jié) 篩檢試驗(yàn)的評(píng)價(jià)Evaluation of Screening test 篩檢試驗(yàn)的評(píng)價(jià)就是將待評(píng)價(jià)的篩檢試驗(yàn)與診斷目標(biāo)疾病的標(biāo)準(zhǔn)方法即“金標(biāo)準(zhǔn)”(gold standard)進(jìn)行同步盲法(blinding)比較,判定該方法對(duì)疾病“診斷”的真實(shí)性和價(jià)值。 篩查方法的評(píng)價(jià)與選擇程序 Procedures of evaluation and selection for screening test 金標(biāo)準(zhǔn) (gold standard)目標(biāo)人群Targetpopulation病人Patient非病人Non-patient待評(píng)價(jià)篩查方法Screening t

14、o be evaluated評(píng)價(jià)指標(biāo)Evaluation indicator一、篩檢試驗(yàn)的評(píng)價(jià)方法 (Evaluation methods)確定金標(biāo)準(zhǔn) (Determine Gold Standard)選擇研究對(duì)象 (Chose Study Subjects)樣本量的估計(jì) (Estimate Sample Size) 整理評(píng)價(jià)結(jié)果 (Sort out evaluation result)第二節(jié) 篩檢試驗(yàn)的評(píng)價(jià)Evaluation of Screening test金 標(biāo) 準(zhǔn)所謂“金標(biāo)準(zhǔn)”是指當(dāng)前臨床醫(yī)學(xué)界公認(rèn)的診斷疾病的最可靠方法Gold StandardThe best available

15、test that is universally recognized by clinical medical circles is called the GOLD STANDARD . 病例組 納入各種類型的病人 對(duì)照組 最好選擇需要與研究疾病鑒別的其他病人,即所選擇的對(duì)照組與病例組具有許多相似的條件研究對(duì)象 Study Subjects Case group Include appropriate spectrum of patients Control group Need to be distinguished to the disease studied, that is the c

16、ontrol has co-morbid conditions with case樣 本 量 Sample Size 影響樣本量的因素待評(píng)價(jià)篩檢試驗(yàn)的靈敏度待評(píng)價(jià)篩檢試驗(yàn)的特異度顯著性水平()允許誤差() Factors determine sample sizeSensitivity of screening to be evaluated Specificity of screening to be evaluated Significance level()Allowable error()當(dāng)待評(píng)價(jià)篩檢試驗(yàn)的靈敏度和特異度均接近50Both sensitivity and specifi

17、city of screening to be evaluated approach 50%n: the number of abnormal (diseased) or normal (healthy) patients in the study.: admissible error. P: the estimation of sensitivity and specificity for testing. ua : the u value for the cumulative probability equal to a/2. 當(dāng)待評(píng)價(jià)篩檢試驗(yàn)的靈敏度和特異度小于20%或大于80%Both

18、 sensitivity and specificity of screening to be evaluated less than 20% or greater than 80% 待評(píng)價(jià)的篩檢試驗(yàn)的估計(jì)靈敏度為75%,特異度55%,計(jì)算病例和對(duì)照組的樣本量設(shè) = 0.05, = 0.08,則:n1 = (1.96/0.08)2(1-0.75)0.75=112.5113n2 = (1.96/0.08)2(1-0.55)0.55=148.6149評(píng)價(jià)該試驗(yàn),病例組為113例,對(duì)照組為149例第二節(jié) 篩檢試驗(yàn)的評(píng)價(jià)本來(lái)有病,被篩檢為陽(yáng)性本來(lái)有病,被篩檢為陰性本來(lái)無(wú)病,被篩檢為陽(yáng)性本來(lái)無(wú)病,被篩檢

19、為陰性評(píng)價(jià)結(jié)果 Evaluation ResultsHave disease, test positiveHave disease, test negativeFree of disease, test positiveFree of disease, test negative評(píng)價(jià)結(jié)果 Evaluation Results 真實(shí)性(validity) 可靠性(reliability) 預(yù)測(cè)值(predictive value)二、篩檢試驗(yàn)的評(píng)價(jià)指標(biāo)Evaluation Index真實(shí)性(validity)也稱效度,指測(cè)量值與實(shí)際值相符合的程度,故又稱準(zhǔn)確性(accuracy)Validity

20、 of test refers to the ability of test to provide a good indication of which apparently well individuals are truly diseased or not diseased.靈敏度(sensitivity)假陰性率(false negative rate)篩檢試驗(yàn)(screening)金標(biāo)準(zhǔn)(gold standard)合計(jì)(total)患者(patient)非患者(non-patient)陽(yáng)性(positive)真陽(yáng)性(TP) A假陽(yáng)性(FP) BR1陰性(negative)假陰性(FN

21、) C真陰性(TN) DR2合計(jì)(total)C1C2N真實(shí)性(validity)特異度(specificity)假陽(yáng)性率(false positive rate)篩檢試驗(yàn)(screening)金標(biāo)準(zhǔn)(gold standard)合計(jì)(total)患者(patient)非患者(non-patient)陽(yáng)性(positive)真陽(yáng)性(TP) A假陽(yáng)性(FP) BR1陰性(negative)假陰性(FN) C真陰性(TN) DR2合計(jì)(total)C1C2N真實(shí)性(validity)正確指數(shù)(Youdens index) (特異度靈敏度)1 1(假陽(yáng)性率假陰性率)真實(shí)性(validity)篩檢試驗(yàn)

22、(screening)金標(biāo)準(zhǔn)(gold standard)合計(jì)(total)患者(patient)非患者(non-patient)陽(yáng)性(positive)真陽(yáng)性(TP) A假陽(yáng)性(FP) BR1陰性(negative)假陰性(FN) C真陰性(TN) DR2合計(jì)(total)C1C2N陽(yáng)性似然比(positive likelihood ratio,LR)陰性似然比(negative likelihood ratio,LR) 真實(shí)性(validity)篩檢試驗(yàn)(screening)金標(biāo)準(zhǔn)(gold standard)合計(jì)(total)患者(patient)非患者(non-patient)陽(yáng)性(p

23、ositive)真陽(yáng)性(TP) A假陽(yáng)性(FP) BR1陰性(negative)假陰性(FN) C真陰性(TN) DR2合計(jì)(total)C1C2N靈敏度(sensitivity) 特異度(specificity)假陽(yáng)性率(false positive rate) 假陰性率(false negative rate)陽(yáng)性似然比(positive likelihood ratio,+LR)陰性似然比(negative likelihood ratio, LR)正確指數(shù)(Youdens index)?真實(shí)性(validity)可靠性(reliability)也稱信度、精確度(precision)或可

24、重復(fù)性(repeatability) 指在相同條件下用某測(cè)量工具(如篩檢試驗(yàn))重復(fù)測(cè)量同一受試者時(shí)獲得相同結(jié)果的穩(wěn)定程度 Validity refers to the ability of test to give consistent results on repeat examinations of the same individual under the same conditions. 標(biāo)準(zhǔn)差與變異系數(shù) coefficient of variance,CV符合率(agreement rate)與Kappa值Screening test 2Screening test 1TotalPo

25、sitiveNegativePositiveABR1NegativeCDR2TotalC1C2N可靠性(reliability) 一致率(agreement rate),符合率一致率可靠性(reliability)Screening test 2Screening test 1TotalPositiveNegativePositiveABR1NegativeCDR2TotalC1C2N取值范圍:-1和1之間Range: between -1 and +1 Kappa值判斷標(biāo)準(zhǔn)Kappa值一致性強(qiáng)度0弱00.2輕0.210.40尚好0.410.60中度0.610.80高度0.811最強(qiáng)可靠性(r

26、eliability)Screening test 2Screening test 1TotalPositiveNegativePositiveABR1NegativeCDR2TotalC1C2NKappa值 = 實(shí)際一致性/非機(jī)遇一致性觀察一致性(Observation consistency) 機(jī)遇一致性(Opportunity consistency) 非機(jī)遇一致性(Non-opportunity consistency)實(shí)際一致性(Actual consistency)可靠性(reliability)Screening test 2Screening test 1TotalPositi

27、veNegativePositiveABR1NegativeCDR2TotalC1C2N 影響可靠性的因素 Determinants of reliability Biological variations of subjectsVariations in different observersVariations in different lab condition受試對(duì)象生物學(xué)變異觀察變異實(shí)驗(yàn)室條件Screening testGold standardTotalPatientNon-patientPositiveTrue Positive AFalse Positive BR1Negati

28、ve False Negative CTrue Negative DR2TotalC1C2N預(yù)測(cè)值(predictive value)陽(yáng)性預(yù)測(cè)值(positive predictive value PPV) 指篩檢試驗(yàn)陽(yáng)性結(jié)果中真正患病(真陽(yáng)性)的比例Screening testGold standardTotalPatientNon-patientPositiveTrue Positive AFalse Positive BR1Negative False Negative CTrue Negative DR2TotalC1C2N預(yù)測(cè)值(predictive value)陰性預(yù)測(cè)值(nega

29、tive predictive value NPV)指篩檢試驗(yàn)陰性者不患目標(biāo)疾病的可能性 第二節(jié) 篩檢試驗(yàn)的評(píng)價(jià)例 人群某病患病狀況與篩檢結(jié)果的關(guān)系 80 245 730 775 210 810 1020篩檢試驗(yàn) 金標(biāo)準(zhǔn) 合計(jì) 患者非患者陽(yáng)性ABR1陰性CDR2合計(jì)C1C2N靈敏度78.6特異度90.1假陽(yáng)性率9.9假陰性率21.4正確指數(shù)0.69陰性似然比0.24陽(yáng)性似然比7.94陰性預(yù)測(cè)值94.2陽(yáng)性預(yù)測(cè)值67.3靈敏度、特異度、患病率與預(yù)測(cè)值的關(guān)系Relationship between sensitivity, specificity, prevalence and predict v

30、alueScreening tests use an arbitrary cut-off to separate two populations (normal vs. abnormal)NumberMeasurementTest with High SensitivityNormalAbnormalA negative result allows you to rule-out whatever you are testing - result+ resultSnNoutScreening tests use an arbitrary cut-off to separate two popu

31、lations (normal vs. abnormal)NumberMeasurementTest with High SpecificityNormalAbnormalA positive result allows you to rule-in whatever you are testing - result+ resultSpPinRelationship between predict value and SN, SPNumber of personsMeasurementNormal AbnormalacdbSN=a/(a+c) 100%, -PV=d(d+c) 100%,SP=

32、d/(b+d) 100%, +PV=a(a+b) 100%,2022/10/6篩檢Example: low prevalence 1% of people have disease out of 1,000 tested (PRE-TEST PROBABILITY) + - + 999 + PV - 1 891 - PV 10 9,990 Sensitivity Specificity 90% 90%2022/10/6篩檢How about a 50% pre-test prob50% of people have disease out of 1,000 tested + - + 450 5

33、0 - 50 450 sitivity Specificity 90% 90%2022/10/6篩檢Lets say its really high: 99%If 99% of people have disease out of 1,000 tested: + 891 1 New- 99 9 Sensitivity Specificity 90% 90%影響預(yù)測(cè)值的因素疾病的患病率患病率下降,陽(yáng)性預(yù)測(cè)值降低靈敏度在患病率不變的情況下,隨著靈敏度的升高,陰性預(yù)測(cè)值升高,陽(yáng)性預(yù)測(cè)值下降特異度隨著特異度的升高,陽(yáng)性預(yù)測(cè)值升高,陰性預(yù)測(cè)值下降圖77 病人與非病人觀測(cè)值分布類型三、篩檢試驗(yàn)截?cái)嘀档拇_定

34、Determination of screening cut-off point 非病人病人某項(xiàng)診斷標(biāo)準(zhǔn)的數(shù)值截?cái)帱c(diǎn)Threshold三、篩檢試驗(yàn)截?cái)嘀档拇_定Determination of screening cut-off point 理想情況Ideal situation人數(shù)NumberNormalDisease非病人Normal病人Abnormal某項(xiàng)診斷標(biāo)準(zhǔn)的數(shù)值Cut-off三、篩檢試驗(yàn)截?cái)嘀档拇_定Determination of screening cut-off point 實(shí)際情況Actual situation人數(shù)Population 96% sensitive 98% s

35、pecific100% sensitive 80% specific 50% sensitive100% specific非病人病人Sensitivity vs. Specificity sensitivity and specificity in different blood sugar level blood sugar SN SP blood sugar SN SP(mg/100ml) () () (mg/100ml) () ( ) 80 100.0 1.2 150 64.3 96.1 90 98.6 7.3 160 55.7 98.6 100 97.1 25.3 170 52.9 9

36、9.6 110 92.9 48.4 180 50.0 99.8 120 88.6 68.2 190 44.3 99.8 130 81.4 82.4 200 37.1 100.0 140 74.3 91.2Relationship between sensitivity and specificity靈敏度與特異度的關(guān)系如果疾病的預(yù)后差,漏掉病人可能帶來(lái)嚴(yán)重后果,且目前又有可靠的治療方法,則臨界點(diǎn)可向左移,盡可能多的發(fā)現(xiàn)人群中的可疑病人,但會(huì)使假陽(yáng)性增多如果疾病的預(yù)后不嚴(yán)重,而現(xiàn)有診療方法不甚理想,臨界點(diǎn)可右移,以降低靈敏度,提高特異度,盡可能將非患者鑒別出來(lái),但增加了假陰性如果假陽(yáng)性者作進(jìn)一步

37、診斷的費(fèi)用太貴,為了考慮節(jié)約經(jīng)費(fèi),可將篩檢試驗(yàn)陽(yáng)性結(jié)果的臨界點(diǎn)向右移如果靈敏度和特異度同等重要,可將篩檢試驗(yàn)陽(yáng)性結(jié)果的臨界點(diǎn)定在非病人的分布曲線與病人的分布曲線的交界處 篩檢試驗(yàn)陽(yáng)性結(jié)果的臨界點(diǎn)的確定Decision of screening cut-off point用真陽(yáng)性率和假陽(yáng)性率作圖得出的曲線,可用于確定篩檢試驗(yàn)的截?cái)嘀?。A receiver operating characteristic (ROC), or simply ROC curve, is a graphical is a graphical plot of the sensitivity, or true positi

38、ves, vs. (1 specificity), or false positives, for a binary classifier system as its discrimination threshold is varied. 受試者工作特性曲線 Receiver operator characteristic curve, ROC糖尿病血糖試驗(yàn)不同血糖水平的靈敏度和特異度分布sensitivity and specificity in different blood sugar level 餐后2小時(shí)血糖mg/100ml)靈敏度()特異度()7098.68.88097.125.5

39、9094.347.610088.669.811085.784.112071.492.513064.396.914057.199.415050.099.616047.199.817042.9100.018038.6100.019034.3100.020027.1100.0血糖測(cè)定診斷糖尿病的ROC曲線截?cái)帱c(diǎn)Cutoff pointROC curve for diagnosis of diabetes using blood glucose橫軸表示假陽(yáng)性率(1-特異度)縱軸表示真陽(yáng)性率(靈敏度)點(diǎn)代表篩檢試驗(yàn)的特定陽(yáng)性標(biāo)準(zhǔn)值相對(duì)應(yīng)的靈敏度和特異度對(duì)子 ROC曲線也可用來(lái)比較兩種和兩種以上診斷試驗(yàn)的

40、診斷價(jià)值,從而幫助臨床醫(yī)師作出最佳選擇 CT和放射性核素腦掃描診斷腦瘤的ROC曲線In comparing two diagnostic tests, the test with the largest area under the ROC curve will have the fewest false positives and false negatives. 第三節(jié) 篩檢效果評(píng)價(jià) Evaluation of effectiveness一、收益選擇患病率高的人群選用高靈敏度的篩檢試驗(yàn)采用聯(lián)合試驗(yàn)串聯(lián)(系列試驗(yàn))并聯(lián)(平行試驗(yàn))YieldTo select the population w

41、ith high prevalence rate To select the test with high sensitivity To design a combine test Series testParallel test 聯(lián)合試驗(yàn) (Combine test )在實(shí)施篩檢時(shí),可采用多項(xiàng)篩檢試驗(yàn)檢查同一受試對(duì)象,以提高篩檢的靈敏度或特異度,增加篩檢的收益,這種方式稱為聯(lián)合試驗(yàn)。A combine test indicate that several tests would be used for a patient, thus, as a whole program, this met

42、hod could increase the tests sensitivity or specificity and enhance yield. 聯(lián)合試驗(yàn)(Combine test )串聯(lián) 全部篩檢試驗(yàn)結(jié)果均為陽(yáng)性者才定為陽(yáng)性可以提高特異度When all tests used turned out positive, the test program reach to a positive result. Series test can increase specificity than one single test, but decrease the sensitivity. 聯(lián)合試

43、驗(yàn)(Combine test )并聯(lián) 全部篩檢試驗(yàn)中,任何一項(xiàng)篩檢試驗(yàn)結(jié)果陽(yáng)性就可定為陽(yáng)性。可以提高靈敏度When one of the tests used turned out positive, the test program reach to a positive result.Parallel test can increase sensitivity than one single test but decrease the specificity. 第三節(jié) 篩檢效果的評(píng)價(jià)OB和OA聯(lián)合試驗(yàn)篩檢大腸癌結(jié)果The found colorectal cancer patients number of combined test 試驗(yàn)結(jié)果 Test results 大腸癌病人Patients非大腸癌病人Not diseased OBOA+-193-+2316+272-669合計(jì) 7590第三節(jié) 篩檢效果的評(píng)價(jià)糞便隱血試驗(yàn)(OB)靈敏度61.33特異度94.44糞便隱白蛋白試驗(yàn)靈敏度66.67特異度80串聯(lián)試驗(yàn)靈敏度36特異度97.78并聯(lián)試驗(yàn)靈敏度92特異度76.67二、篩檢的生物學(xué)效果評(píng)價(jià)Biological effectiveness evaluation病死率、死亡率、生存率篩檢組Screened group未篩檢組Unscreened group比較Fata

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論